Page 3 - Life Edit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets. With a focus on advancing base editing capabilities, Novo Nordisk will leverage Life Edit’s suite of gene editing technologies to precisely edit the genome with the aim of developing life-changing therapies for rare genetic disorders as well as more prevalent cardiometabolic diseases.

Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on global

By Dominic Chopping Novo Nordisk said Wednesday that it has established a collaboration deal with Life Edit Therapeutics to discover and develop gene-editing therapies. The Danish... | May 24, 2023

Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on... | May 24, 2023

Capitalising on strong demand for its obesity therapies, Novo Nordisk's growing appetite for deals has fuelled a bet on a U.S. gene-editing company called Life Edit Therapeutics.